The estimated Net Worth of Jason B. Shandell is at least $10.3 Million dollars as of 5 February 2020. Jason Shandell owns over 44,401 units of Amphastar Pharmaceuticals Inc stock worth over $6,568,998 and over the last 10 years Jason sold AMPH stock worth over $3,735,049.
Jason has made over 28 trades of the Amphastar Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Jason exercised 44,401 units of AMPH stock worth $639,374 on 5 February 2020.
The largest trade Jason's ever made was exercising 56,996 units of Amphastar Pharmaceuticals Inc stock on 26 September 2016 worth over $622,966. On average, Jason trades about 10,021 units every 30 days since 2014. As of 5 February 2020 Jason still owns at least 145,751 units of Amphastar Pharmaceuticals Inc stock.
You can see the complete history of Jason Shandell stock trades at the bottom of the page.
Jason's mailing address filed with the SEC is C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA, CA, 91730.
Over the last 10 years, insiders at Amphastar Pharmaceuticals Inc have traded over $72,457,295 worth of Amphastar Pharmaceuticals Inc stock and bought 66,100 units worth $921,987 . The most active insiders traders include Jack Y.Luo Mary Z. Zhang, Richard K Prins, and William J Peters. On average, Amphastar Pharmaceuticals Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,459,051. The most recent stock trade was executed by Floyd F. Petersen on 5 September 2024, trading 3,000 units of AMPH stock currently worth $139,410.
amphastar pharmaceuticals, inc., headquartered in rancho cucamonga, california, established in 1996, is a recognized specialty pharmaceutical company that uses state-of-the-art, cgmp compliant facilities to develop, manufacture, and market injectable and inhalation products. in addition to the corporate headquarters, amphastar has five manufacturing facilities located in the united states, china and europe along with a state-of-the-art new drug research center. amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. we currently produce approximately 15 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the u.s. enables it to establish significant market share upon the int
Amphastar Pharmaceuticals Inc executives and other stock owners filed with the SEC include: